RoosterBio, a leading supplier of human mesenchymal stem/stromal cells (hMSCs) and advanced therapy manufacturing solutions, has partnered exclusively with Shanghai-based MineBio Life Sciences Limited to deliver its research-grade and CliniControl cGMP media platforms across China.

 

MineBio, already holding import approval for RoosterBio’s media, can now fulfill orders immediately, eliminating delays for Chinese developers of cell and gene therapies.

 

“China has emerged as a global leader in MSC and exosome clinical research, with one of the highest concentrations of active trials anywhere in the world,” said Tim Kelly, CEO of RoosterBio. 

 

“We have long sought the right partner to bring our platform to this market — someone who is deeply embedded in the Chinese cell and gene therapy community and genuinely trusted by the developers working to bring these therapies to patients. 

 

"MineBio’s expertise, robust customer network, and commitment to quality make them the ideal collaborator to expand access to RoosterBio’s RUO and cGMP media solutions. We are thrilled to work together to help China’s innovators increase their productivity and move faster from the bench to the clinic.”

 

RoosterBio’s CliniControl line supports the full spectrum of MSC and exosome product development, from early research to cGMP manufacturing. The platform includes MSC expansion media, exosome collection media, bioreactor feeds, and genetic engineering media, all backed by FDA Type II Master Files and global regulatory support.

 

China’s regenerative medicine sector is booming, with an increasing number of MSC and exosome clinical trials. MineBio’s extensive network and technical expertise position it to deliver RoosterBio’s solutions efficiently to developers across the country.

 

“RoosterBio delivers far more than just cGMP media; they provide a complete, built-in biomanufacturing platform,” said Amy Zuo, General Manager of MineBio Life Sciences. 

 

“As a premier provider of GMP manufacturing materials, tools, and turnkey solutions for China’s CGT sector, MineBio knows our clients urgently need scalable systems that comply with stringent Chinese and international regulatory standards (including NMPA, FDA, and EMA), while radically reducing the total cost of ownership. 

 

"By integrating RoosterBio’s globally recognized, Master File-backed products with our extensive CGT supply chain and technical expertise, we empower Chinese developers to confidently accelerate their dual US-China and global IND pipelines. We are fully prepared to drive our customers’ clinical and commercial success from day one.”